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Abstract: The application of liposuctioned white adipose tissue (L-WAT) and adipose-derived
stem cells (ADSCs) as a novel immunomodulatory treatment option is the currently subject of
various clinical trials. Because it is crucial to understand the underlying therapeutic mechanisms,
the latest studies focused on the immunomodulatory functions of L-WAT or ADSCs. However,
studies that examine the specific transcriptional adaptation of these treatment options to an extrinsic
inflammatory stimulus in an unbiased manner are scarce. The aim of this study was to compare
the gene expression profile of L-WAT and ADSCs, when subjected to tumor necrosis factor alpha
(TNFα), and to identify key factors that might be therapeutically relevant when using L-WAT or
ADSCs as an immuno-modulator. Fat tissue was harvested by liposuction from five human donors.
ADSCs were isolated from the same donors and shortly subjected to expansion culture. L-WAT and
ADSCs were treated with human recombinant TNFα, to trigger a strong inflammatory response.
Subsequently, an mRNA deep next-generation sequencing was performed to evaluate the different
inflammatory responses of L-WAT and ADSCs. We found significant gene expression changes in both
experimental groups after TNFα incubation. However, ADSCs showed a more homogenous gene
expression profile by predominantly expressing genes involved in immunomodulatory processes such
as CCL19, CCL5, TNFSF15 and IL1b when compared to L-WAT, which reacted rather heterogeneously.
As RNA sequencing between L-WAT and ADSCS treated with TNFα revealed that L-WAT responded
very heterogeneously to TNFα treatment, we therefore conclude that ADSCs are more reliable and
predictable when used therapeutically. Our study furthermore yields insight into potential biological
processes regarding immune system response, inflammatory response, and cell activation. Our results
can help to better understand the different immunomodulatory effects of L-WAT and ADSCs.
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1. Introduction
Inflammation is a complex, multifaceted state for many chronic conditions. The ability to
regulate an adequate inflammatory response is pivotal to prevent the development and progression
of any disease. Inflammatory processes are characterized by an interplay between pro- and
anti-inflammatory cytokines. Cytokines, such as interleukin-1 (IL-1), tumor necrosis factor (TNF)
and gamma-interferon (IFN-γ), are classified as pro-inflammatory, whereas IL-4, IL-10 and IL-14
are classified as anti-inflammatory cytokines [1–3]. However, this classification is far too simplistic,
since most cytokines may act as a pro- as well as an anti-inflammatory cytokine [1,4]. In many
chronic diseases, such as osteoarthritis, rheumatoid arthritis and Crohn’s disease, the balance of
pro- and anti-inflammatory cytokines shifts toward pro-inflammatory factors and ultimately requires
treatment [5]. Thus, novel treatment options targeting cytokine imbalance in inflammatory conditions
are under investigation.
Human white fat cells and stem cells, derived of white fat tissue (ADSCs), have been shown
to exert immunomodulatory effects both in vitro and in vivo [6–8]. White adipose tissue (WAT) is a
highly complex organ. Rather than functioning as a mere energy storage, it also plays a potent role in
metabolic and endocrine balance. It is composed of adipocytes, loose connective tissue matrix and
the stromal vascular fraction (SVF). The SVF consists of preadipocytes, capillary endothelial cells,
infiltrated monocytes/macrophages and a small subpopulation of multipotent ADSCs. The cellular
composition, cell size and cell activity are highly variable and dependent on the donor and the tissue
source [9–11]. Similar therapeutic effects are described for both WAT and ADSCs, yet there is a trend
in regenerative and immunomodulatory medicine toward the utilization of the supposedly more
versatile ADSCs. They are thought to be the most promising cells of the SVF regarding medical
benefits [12–17], and their molecular features make them promising candidate cells, not only in the
field of regenerative medicine, but also for the treatment of inflammatory-related disorders [7,18–24].
ADSCs can exert immunomodulation through direct contact with immune cells or by secretion of
paracrine factors [5,7,8]. Dependent on their microenvironment, ADSCs exhibit pro-inflammatory and
anti-inflammatory properties [6]. ADSCs have the ability to interact with many components of the
innate immune system, including soluble complement, macrophages, dendritic cells, neutrophils, mast
cells and natural killer cells [6,25,26]. Furthermore, ADSCs have the capacity to interfere with the
adaptive immune system [27–29]. For clinical purposes, ADSCs have been used as anti-inflammatory
“bioreactors” in the case of inflammatory bowel diseases, osteoarthritis, diabetes mellitus, chronic
wounds and scar treatment [13–15,19,30–32]. Nevertheless, there is still some ambiguity regarding the
utilization of ADSCs as a cellular treatment option. Potentially harmful short- or long-term effects may
still be discovered, and as the exact working mechanisms are yet to be unraveled, the application as a
treatment option is legally restricted in most countries.
In contrast, the use of simple WAT for clinical purposes is not subject to such strict legal
restrictions in most countries, as long as it is used as an unpurified autologous lipo-transfer. Current
clinical applications include scar treatment, breast reconstruction after breast cancer surgery, aesthetic
rejuvenation, cleft-lip repair and liposculpture for body deformities [30,33–36]. The treatment of bone
defects, osteomyelitis or chronic wounds is being debated [13,30,35–39]. Although having a higher
immunomodulatory and regenerative potential, the clinical use of purified ADSCs is, as mentioned
above, even more restricted. Given the huge potential of treating chronic inflammatory processes with
the more appealing ADSCs, the mechanisms of action need to be further explored in order to facilitate
legalization of future clinical applications.
For this purpose, we aimed to generate an unbiased dataset of transcriptional changes after
an extrinsic inflammatory stimulus. Therefore, liposuctioned white fat tissue (L-WAT) and ADSCs
from the same donor were treated with tumor necrosis factor alpha (TNFα) in vitro. Subsequently,
a bioinformatic analysis of obtained RNA sequencing was performed to evaluate the different
inflammatory responses of L-WAT and ADSCs.
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2. Results
2.1. Gene Expression after TNFα Treatment of ADSCs Is More Homogenous in Comparison to L-WAT
To assess the immunomodulatory response of L-WAT and ADSPC of the same donor after TNFα
exposure, we performed a deep RNA-sequencing (Figure 1).
Figure 1. Experimental timeline and setup. Human L-WAT was harvested from five different donors
through water-jet-assisted liposuction. Fresh fat samples were incubated with TNFα for 48 h, to mimic
an inflammatory milieu that triggers a strong immune response. Simultaneously, ADSCs were isolated
from the same donors’ fat samples harvested during earlier liposuction. After an expansion period
of 72 h, ADSCs were also treated with TNFα. Subsequently the incubation with TNFα, RNA from
fat and cell samples was isolated and sequenced. A portion of the same sample without TNFα was
implemented in parallel and used as reference control.
TNFα induced significant changes in gene expression in L-WAT and ADSCs, when compared
to controls. After normalization and correction for multiple testing, differential gene expression
analysis revealed 83 genes that were significantly upregulated and 29 genes that were significantly
downregulated in L-WAT treated with TNFα, when compared to untreated L-WAT. Interestingly,
ADSCs from different donors showed a considerably more homogenous transcriptional response, which
results in 1404 and 1109 genes that were significantly upregulated and downregulated, respectively,
in ADSCs treated with TNFα, when compared to ADSCs in normal culture conditions. Common to
both groups, 68 genes were significantly upregulated, and 11 genes were significantly downregulated.
While Table 1 shows the five most TNF-dependent upregulated and downregulated genes, when
comparing ADSCs to ADSCs, and TNFα or L-WAT to L-WAT and TNFα (Table 1), Supplementary
Table S1 (Table S1) includes all significantly changed genes of ADSCs and L-WAT after TNFα treatment.
Table 1. Five most TNFα-dependent upregulated and downregulated in ADSCs and L-WAT; logFC:
logarithmic fold-change.
ADSCs vs. ADSCs and TNFα
Gene symbol Description logFC
CXCL10 C-X-C motif chemokine ligand 10 10.08
CXCL11 C-X-C motif chemokine ligand 11 9.67
CCL5 C-C motif chemokine ligand 5 9.60
CXCL8 C-X-C motif chemokine ligand 8 9.38
LINC01539 long intergenic non-protein coding RNA 1539 8.49
PLA2G2A phospholipase A2 group IIA −6.22
WISP2 WNT1 inducible signaling pathway protein 2 −6.47
TNNT3 troponin T3, fast skeletal type −6.48
ASPN Asporin −7.06
H19 H19, imprinted maternally expressed transcript −8.17
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Table 1. Cont.
L-WAT vs. L-WAT and TNFα
Gene symbol Description logFC
CCL22 C-C motif chemokine ligand 22 5.68
ANO9 anoctamin 9 5.30
MMP9 matrix metallopeptidase 9 5.17
EBI3 Epstein–Barr virus induced 3 4.94
CCL5 C-C motif chemokine ligand 5 4.68
ECSCR endothelial cell surface expressed chemotaxis and apoptosis regulator −2.97
AC091939.1 novel transcript −3.13
MNDA myeloid cell nuclear differentiation antigen −3.57
CA4 carbonic anhydrase 4 −4.08
AC002546.1 novel transcript −4.13
2.2. Gene Expression Regulation in Fat and ADSCs Treated with TNFα
To further highlight the different gene expression response of L-WAT and ADSCs to TNFα
treatment, we analyzed the significantly upregulated and downregulated genes in the L-WAT vs.
ADSCs, as well as in the experimental group L-WAT and TNFα vs. ADSCs and TNFα. We found
3388 genes significantly higher expressed in ADSCs, in contrast to L-WAT. Furthermore, our evaluation
showed 2397 significantly higher expressed genes in ADSCs and TNFα, when compared to L-WAT
and TNFα. Interestingly, 699 genes out of the 2397 significantly upregulated genes in ADSCs were
TNFα-dependent (Figure 2A). In comparison, 3129 genes were significantly lower expressed in ADSCs,
when compared to L-WAT. After incubation with TNFα, 3047 genes were significantly downregulated
in ADSCs, when compared to L-WAT. Hereof, 1160 genes were significantly downregulated in ADSCs
and TNFα, when compared to L-WAT and TNFα, due to the effect of TNFα. The remaining 1887
significantly downregulated genes in ADSCs and TNFα, when compared to L-WAT and TNFα were
not related to the effect of TNFα (Figure 2B). The whole list of significantly changed genes in ADSCs
and TNFα vs. L-WAT and TNFα is provided in Supplementary Table S2 (Table S2).
Figure 2. Significantly differentially expressed genes in L-WAT and ADSCs. Significantly upregulated
genes in ADSCs compared to L-WAT and in ADSCs and TNFα compared to L-WAT and TNFα (A).
Significantly, downregulated genes in ADSCs compared to L-WAT and in ADSCs and TNFα compared
to L-WAT and TNFα (B).
While a hierarchical cluster analysis of the principal component 1 (PC1), revealed a clear
separation of ADSCs and L-WAT, PC4 clearly shows that ADSCs have a substantial higher homogenous
gene expression profile, when compared to L-WAT (Figure 3). Moreover, ADSCs showed greater
transcriptome changes after incubation with TNFα, when compared to L-WAT (Figure 3, PC4).
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Figure 3. Principal Component Analysis (PCA) of L-WAT and ADSCs. The PCA revealed a clear
separation of L-WAT (blue dots) and ADSCs (red dots) along the main component PC1. In addition,
TNFα treatment showed a separation along PC4, with a more homogeneous response of ADSCs
(dark-red dots), when compared to L-WAT (dark-blue dots). There was no clear clustering of samples
from the abdomen (black border) or the thighs (no border).
The 30 most to PC1 contributing genes are fat-related marker genes, including LEP, FABP4
and ADIPOQ. Furthermore, it revealed six genes that are higher expressed in ADSCs; these include
GREM1, known to be involved in limb development [40], CNN1, which plays a role in smooth-muscle
function [41], and ALPK2, which is important for cardiac muscle cell development [42] (Figure 4A).
Interestingly, the analysis of the fourth cluster (PC4) revealed the separation among genes
associated with immunomodulatory processes such as CX3CL1, IL-4I1, IL-31 and CCL5. (Figure 4B).
However, this separation was strongly visible in ADSCs, whereas, in L-WAT, the inflammatory
effect was not as strong. The top five prominent genes in this separation are as follows: BIRC3,
which is important for the inhibition of apoptosis [43]; MEOX1, which plays a role in sclerotome
development [44]; CX3CL1, which is pivotal for chemotaxis and cell adhesion [45]; CCL19, which
plays a crucial role in different inflammatory processes [46,47]; and ANO9, which might play a role in
different types of cancer [48].
Figure 4. Hierarchical cluster analysis of the 30 most contributing genes of PC1 and PC4. The 30
most to PC1 contributing genes are fat-related marker genes including LEP, FABP4 and ADIPOQ
(A). The analysis of the PC4 reveals the separation among genes associated with immunomodulatory
processes (B).
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2.3. Biological Pathways that Are Regulated Upon TNFα Exposure in L-WAT and ADSCs
As TNFα is a pleiotropic cytokine with important functions, such as homeostasis, inflammation,
pathogenesis, apoptosis or necroptosis [49], different biological processes were significantly changed
in the experimental groups after exposure to TNFα. We carried out pathway and functional analysis,
using Gene Ontology (GO), including all genes that were differentially regulated upon L-WAT and
ADSCS treated with TNFα (ADSCs and TNFα vs. L-WAT and TNFα). The evaluation with GO of all
significantly higher regulated genes in ADSCs, when compared to L-WAT treated with TNFα, revealed
a plentitude of different biological functions, like immune system processes, extracellular matrix
organization and response to an inflammatory stimulus (Figure 5A). Furthermore, the analysis with
GO of significantly lower-expressed genes in ADSCs, when compared to L-WAT treated with TNFα,
showed alterations in different biological pathways, including developmental processes, biological
adhesion and leukocyte migration (Figure 5B). The whole list of significantly different biological
processes is provided in Supplementary Table S3 (Table S3).
Figure 5. Significantly changed biological pathways in ADSCs and L-WAT after incubation with
TNFα. Differential gene expression analysis revealed hundreds of significant upregulated (A) and
downregulated (B) biological pathways in ADSCs treated with TNFα, when compared to L-WAT
treated with TNFα.
To get a better understanding of the differentially regulated pathways in ADSCs and L-WAT
upon exposure to TNFα, we performed a gene set enrichment analysis (GSEA). Interestingly, ADSCs
and TNFα showed a significant increase of inflammation-related gene hallmarks, as well as gene
hallmarks, like epithelial to mesenchymal transition and apical junctions, when compared to L-WAT
and TNFα (Figure 6). Intriguingly, while TNFα exposure of ADSCs led to interferon alpha-, as well as
gamma-related response, L-WAT showed a mild response in the interferon gamma pathway and nearly
no gene-set enrichment in the interferon alpha hallmark (Figure 6, blue arrowheads). Additionally,
the most significantly underrepresented gene sets of ADSCs and TNFα mainly consist of fat-related
metabolism and development sets, when compared to L-WAT and TNFα (Figure 6).
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Figure 6. Visualization of the five most positively (NES > 0) or negatively (NES < 0) TNFα-dependent
hallmark gene sets in ADSCs, when compared to L-WAT. Blue arrowheads indicate the difference of
interferon alpha and gamma response of ADSCs and L-WAT upon TNFα treatment. NES: normalized
enrichment score. Adjusted p-value < 0.05.
3. Discussion
L-WAT and ADSCs are seen as a promising therapy tools in the field of regenerative medicine.
While the use of simple fat tissue is straightforward, the therapeutic use of isolated stem cells is
controversial and, to date, not clinically approved in most countries. Because of the inflammatory
component, which characterize several clinical conditions, it is of upmost importance to discover
novel immunomodulatory treatment options and to understand their mechanisms of action. To date,
there are several studies that investigated the immunomodulatory function of (L-)WAT and ADSCs,
but to our knowledge, there is none specifically investigating the differences in both in an unbiased
manner [20,50–52]. In the early 2000s, Zuk et al. described the in vitro potential of human ADSCs to
differentiate under specific culture conditions into different mesenchymal cell linages [16,53]. Later,
mesenchymal stem cells and ADSCs were introduced as trophic mediators for tissue repair, and it
was proposed that they secrete factors that stimulate the release of functional bioactive factors from
surrounding cells [54,55]. This view has been evolved, and MSCs and ADSCs are now believed to
secrete paracrine factors themselves that promote cell viability, proliferation and matrix production
in the surrounding environment [55]. Different studies show that the secretome of ADSCs, exerted
through extracellular vesicles, is a promising source of new cell-free therapies in the field of regenerative
medicine [24,56–61]. The identification of the exact overall immunomodulatory response of L-WAT
and ADSCs is crucial for clinical approaches, in order to introduce targeting therapies. Therefore, our
aim was to investigate the differences in the inflammatory response of L-WAT and ADSCs.
In our study, we identified genes in L-WAT and ADSCs, as well as pathways induced or repressed
in inflammation that are modulated by TNFα exposure and may represent candidates for targeting
treatment in inflammatory conditions. As expected, the analysis detected genes specifically involved
in TNFα-induced inflammatory processes. After correction for multiple testing, 5444 genes showed
significant differential gene expression in ADSCs treated with TNFα, when compared to L-WAT treated
with TNFα. Our data provide evidence that ADSCs display greater transcriptional changes after
TNFα treatment, when compared to L-WAT (Figure 3). The PCA clearly shows that ADSCs display a
more homogenous gene expression between cells isolated from different individuals, when compared
to a strong heterogeneous gene expression profile in L-WAT. This fact might indicate that L-WAT is
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much more susceptible to inter-individual factors and thus might influence its therapeutic effect. This
appears to be even more interesting, when considering the circumstance that isolated ADSCs and fat
tissue were harvested from the same donors.
WAT is a whole tissue with its intrinsic and complex cellular and biochemical components, which
makes its clinical use difficult. In addition, inter-individual donor factors, such as age, sex, ancestry and
medical conditions, have a hardly predictable and yet unknown influence on the therapeutical outcome.
Furthermore, WAT contains not only progenitor cells, but also adipocytes, blood cells, immune cells
and soluble factors that can influence the gene expression profile. On the other hand, since WAT is
composed of different components, it might be concluded that when used for therapeutic purposes,
these components can synergistically exert their positive effects. Different studies showed that ADSCs
cannot exert their claimed therapeutic effects solitary but need different “co-factors” [50]. Furthermore,
ADSCs injected into osteoarthritic joints are not detectable anymore after a few days [62,63]. Therefore,
it is assumed that ASPCs “imprint” their anti-inflammatory effects on cells of the immune system,
which then give a prolonged ameliorating effect [15,62,63]. These findings indicate that a composition
of progenitor cells and different cells of the immune system, as found in L-WAT, might have a stronger
positive therapeutic effect than its individual injected factors. On the other hand, isolated ADSCs
are referred to be the most promising and potent component of L-WAT, because these cells behave
in a more predictable manner [13,17,20,64]. Different studies have shown that an inflammatory
environment, as found in many chronic diseases, extensively enhances the immunosuppressive effects
of ADSCs [65]. However, it remains uncertain if there is a special “threshold” that needs to be reached
to activate the immunomodulatory effects of L-WAT and ADSCs. Therefore, searching for the strategies
that can activate the trophic functions of L-WAT and ADSCs is fundamental for their application in
regenerative medicine.
While an inflammatory response to TNFα treatment was shown in all donors, the effect of TNFα
seemed to be stronger in ADSCs. This might be mostly due to the highly heterogeneous gene expression
profile and the high proportion of fat-related gene sets in L-WAT treated with TNFα, which may
alleviate its inflammatory effect. Another limitation of the presented study is the utilization of ADSCs
and L-WAT from different anatomical regions and the in vitro expansion of ADSCs, as the complexity of
the immunomodulatory action of ADSCs and WAT cannot be resolved by pure in vitro experiments [66].
Nonetheless, our GSE analysis revealed that gene sets for interferon alpha and gamma were differently
regulated between ADSCs and L-WAT upon TNFα treatment. This novel result can be utilized in future
experiments, by confining genes that are involved in the immunomodulatory properties of ADSCs.
Future studies should focus on the direct transcriptional analysis of WAT in different inflammatory
conditions (IFNα/β, IFNγ and/or TNFα), on a single-cell level, to obtain biologically relevant data.
This experimental approach will help to unravel the interactions between the various cell types of
WAT, including ADSCs.
4. Materials and Methods
4.1. Ethics Statement and Sample Acquisition
After obtaining written informed consent, human L-WAT was obtained from five patients
without systemic diseases (mean age: 47.4 years), undergoing water-jet-assisted liposuction with
the Body-Jet system (human med AG, Germany) from subcutaneous regions, for aesthetic reasons.
Liposuctions with the Body-Jet system were performed with 3.5 and/or 3.8 mm cannulas and a
pressure of approximately 550 bar. This study was conducted in accordance with the declaration of
Helsinki and approved by the ethics committee of Ludwig-Maximilians-University, Munich (275-16).
All lipoaspirates were harvested from the abdomen or thighs, through liposuction by a surgeon
following common surgical standards. All patients were previously screened and tested negative for
HIV (human immunodeficiency virus), HCV (hepatitis C virus) and HBV (hepatitis B virus). Patients’
information is summarized in Supplementary Table S4.
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4.2. Preparation of White Adipose Tissue, Cell Isolation and Culture Conditions
For all samples, a portion of 1.5 g L-WAT was washed twice with phosphate-buffered saline
(PBS), to remove residual blood, and afterward they were directly incubated in standard culture
medium, consisting of DMEM-high glucose (Thermo Fisher Scientific, USA) supplemented with 10%
fetal bovine serum (FBS, Sigma-Aldrich, USA), 100 U/mL of Penicillin and 100 µg/mL of Streptomycin
(Life Technology, USA), in a humidified incubator (21% O2, 5% CO2 and 37 ◦C), supplemented
with 50 ng/mL of recombinant TNFα (Merck, Germany), for 48 h, to stimulate the secretion of
inflammatory paracrine factors. ADSCs were isolated from approximately 10 g of the same L-WAT
with a semi-automated centrifuge system (ARC™-Processing Unit, InGeneron, USA), following the
manufacturer’s protocol and using its enzyme blend (Matrase™) and 37 ◦C warm lactated Ringer’s
solution (Fresenius Kabi, Germany). Stem cell properties were proven by differentiating a proportion
of isolated cells into the osteogenic, adipogenic and chondrogenic lineage, as previously published [67].
For RNA-Seq experiments, freshly isolated cells were expanded for 3 days in standard culture medium,
as described above. After cell expansion for 72 h, 150,000 ADSCs in passage 1 were cultured for an
additional 48 h in standard culture medium, supplemented with 50 ng/mL recombinant TNFα. ADSCs
and L-WAT in standard culture medium in the absence of TNFα served as a control. ASCs after 72 h
(ASC 0 h) and fresh L-WAT after washing (L-WAT 0 h) served as baseline controls. After cultivation,
ADSCs and L-WAT were lysed in Trizol (Invitrogen, USA) and stored at −80 ◦C, until RNA sequencing.
4.3. Deep RNA-Sequencing and Bioinformatics
Total RNA was isolated by following a standardized protocol. RNA quality and quantity were
measured with a BioAnalyzer (Agilent, USA), and libraries for sequencing were prepared with
a SENSE mRNA-Seq Library Prep Kit V2 (Lexogen, Austria). All libraries were sequenced on a
HiSeq1500 device (Illumina, USA) with a read length of 50 bp and a sequencing depth of approximately
20 million reads per sample. After demultiplexing, reads were aligned to the human reference genome
(version GRCH38.85) with STAR (version 2.5.3a) [68]. Expression values (TPM) were calculated
with RSEM (version 1.3.0) [69]. Genes detected in less than five samples were removed from further
analysis. Differential gene expression analysis was performed, using the “voom” function in edgeR
(version 3.26.5) [70] with a linear model encompassing biological condition and sequencing lane as
fixed and random effect, respectively. An adjusted p-value (FDR) of less than 0.05 was set to determine
significantly changed genes.
5. Conclusions
Autologous fat grafting has been carried out for decades as a standard procedure in many fields
of plastic and reconstructive surgery, whereas the use of isolated ADSCs is highly restricted in most
countries. In this study, we show that both L-WAT and ADSCs exhibit a strong response when
exposed to an inflammatory environment. However, the inflammatory effect of TNFα on transcriptome
regulation is more pronounced and predictable in ADSCs, when compared to L-WAT, which displays
a very heterogeneous gene expression profile.
Supplementary Materials: The total list of significant differentially expressed genes (DEGs) of ADSCs and L-WAT
after TNF treatment, as well as DEGs of ADSCs and TNFα compared to L-WAT and TNFα and corresponding
changed gene ontologies, are provided in Supplementary Tables S1–S3. Patients’ information is provided in
Supplementary Table S4. All supplementary tables can be found at http://www.mdpi.com/1422-0067/21/3/1086/s1.
All sequencing raw data is available upon request and approval of the local ethics committee.
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Abbreviations
ADSCs adipose-derived stem cells
GO gene ontology
GSEA gene set enrichment analysis
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
IFN Interferon
IL Interleukin
L-WAT liposuctioned white adipose tissue
PCA principal component analysis
SVF stromal vascular fraction
TNFα tumor necrosis factor alpha
WAT white adipose tissue
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